Sumitomo Pharma Overview
- Year Founded
-
1897
- Status
-
Public
- Employees
-
3,123
- Stock Symbol
-
4506
- Investments
-
32
- Share Price
-
$12.68
- (As of Friday Closing)
Sumitomo Pharma General Information
Description
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Website
www.sumitomo-pharma.comCorporate Office
- 6-8 Doshomachi 2-Chome
- Chuo-ku
- Osaka, 541-0045
- Japan
Corporate Office
- 6-8 Doshomachi 2-Chome
- Chuo-ku
- Osaka, 541-0045
- Japan
Sumitomo Pharma Stock Performance
As of 13-Nov-2026, Sumitomo Pharma’s stock price is $12.68. Its current market cap is $5.69B with 449M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.68 | $12.35 | $7.54 - $21.40 | $5.69B | 449M | 3.97M | $0.68 |
Sumitomo Pharma Financials Summary
As of 30-Sep-2026, Sumitomo Pharma has a trailing 12-month revenue of $3.13B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 5,122,333 | 6,356,884 | 3,755,778 | 3,496,261 |
| Revenue | 3,130,322 | 3,007,426 | 2,615,324 | 2,177,025 |
| EBITDA | 356,503 | (2,194,576) | ||
| Net Income | 293,823 | 709,007 | 154,979 | (2,179,870) |
| Total Assets | 5,406,394 | 5,033,036 | 4,962,525 | 5,996,075 |
| Total Debt | 887,407 | 1,358,618 | 2,041,013 | 2,767,651 |
Sumitomo Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sumitomo Pharma Comparisons
Industry
Financing
Details
Sumitomo Pharma Competitors (32)
One of Sumitomo Pharma’s 32 competitors is Chugai Pharmaceutical, a Corporate Backed or Acquired company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Chugai Pharmaceutical | Corporate Backed or Acquired | Tokyo, Japan | ||||
| Otsuka Holdings | Corporation | Tokyo, Japan | ||||
| Shionogi | Corporation | Osaka, Japan | ||||
| Ipsen | Formerly PE-Backed | Paris, France | ||||
| Cipla | Corporation | Mumbai, India |
Sumitomo Pharma Patents
Sumitomo Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026225630-A1 | Combinational use of antitumor agents | Pending | 25-Apr-2025 | ||
| WO-2026211719-A1 | Method for producing azabicyclo ring derivative | Pending | 31-Mar-2025 | ||
| WO-2026205131-A1 | Substituted pyridine and substituted pyridazine derivatives | Pending | 26-Mar-2025 | ||
| WO-2026163623-A1 | Focused ultrasound irradiation system and control method for focused ultrasound irradiation system | Pending | 28-Jan-2025 | ||
| WO-2026160418-A1 | Method for producing triazine derivative, and intermediate for production of said derivative | Pending | 24-Jan-2025 |
Sumitomo Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sumitomo Pharma Investments & Acquisitions (32)
Sumitomo Pharma’s most recent deal was a Joint Venture with RACTHERA. The deal was made on 15-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RACTHERA | 15-Nov-2024 | Joint Venture | Biotechnology | ||
| Nabriva Therapeutics (Assets in the U.S., Ireland and Austria) | 30-Jul-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Myovant Sciences | 10-Mar-2023 | Secondary Transaction - Open Market | Biotechnology | ||
| AlphaNavi Pharma | 01-Mar-2023 | Early Stage VC | Drug Discovery | ||
| Immunosens | 02-Feb-2023 | Later Stage VC | Diagnostic Equipment |
Sumitomo Pharma ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Sumitomo Pharma Exits (10)
Sumitomo Pharma’s most recent exit was on 30-Sep-2021 from Roivant Sciences. The exit was categorized as with 8 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Roivant Sciences | 30-Sep-2021 | Completed |
|
||
| Drawbridge Health | 26-Oct-2020 | Completed |
|
||
| MediGear International | 01-Feb-2020 | Completed |
|
||
| Roivant Sciences | 03-Jan-2020 | Completed |
|
||
| Spirovant Sciences | 30-Dec-2019 | Merger/Acquisition | Completed |
Sumitomo Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sumitomo Pharma (Asia Operations) | Japan |
Sumitomo Pharma FAQs
-
When was Sumitomo Pharma founded?
Sumitomo Pharma was founded in 1897.
-
Where is Sumitomo Pharma headquartered?
Sumitomo Pharma is headquartered in Osaka, Japan.
-
What is the size of Sumitomo Pharma?
Sumitomo Pharma has 3,123 total employees.
-
What industry is Sumitomo Pharma in?
Sumitomo Pharma’s primary industry is Drug Discovery.
-
Is Sumitomo Pharma a private or public company?
Sumitomo Pharma is a Public company.
-
What is Sumitomo Pharma’s stock symbol?
The ticker symbol for Sumitomo Pharma is 4506.
-
What is the current stock price of Sumitomo Pharma?
As of 13-Nov-2026 the stock price of Sumitomo Pharma is $12.68.
-
What is the current market cap of Sumitomo Pharma?
The current market capitalization of Sumitomo Pharma is $5.69B.
-
What is Sumitomo Pharma’s current revenue?
The trailing twelve month revenue for Sumitomo Pharma is $3.13B.
-
Who are Sumitomo Pharma’s competitors?
Chugai Pharmaceutical, Otsuka Holdings, Shionogi, Ipsen, and Cipla are some of the 32 competitors of Sumitomo Pharma.
-
What is Sumitomo Pharma’s annual earnings per share (EPS)?
Sumitomo Pharma’s EPS for 12 months was $0.68.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
